- Home
- CRI vs GERN Comparison
CRI vs GERN Comparison
Compare CRI & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRI
- GERN
- Stock Information
- Founded
- CRI 1865
- GERN 1990
- Country
- CRI United States
- GERN United States
- Employees
- CRI N/A
- GERN N/A
- Industry
- CRI Apparel
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- CRI Consumer Discretionary
- GERN Health Care
- Exchange
- CRI Nasdaq
- GERN Nasdaq
- Market Cap
- CRI 1.8B
- GERN 1.5B
- IPO Year
- CRI 2003
- GERN 1996
- Fundamental
- Price
- CRI $52.07
- GERN $2.57
- Analyst Decision
- CRI Hold
- GERN Strong Buy
- Analyst Count
- CRI 6
- GERN 11
- Target Price
- CRI $67.67
- GERN $6.82
- AVG Volume (30 Days)
- CRI 802.9K
- GERN 12.4M
- Earning Date
- CRI 02-25-2025
- GERN 02-26-2025
- Dividend Yield
- CRI 6.15%
- GERN N/A
- EPS Growth
- CRI 15.51
- GERN N/A
- EPS
- CRI 6.33
- GERN N/A
- Revenue
- CRI $2,842,254,000.00
- GERN $29,480,000.00
- Revenue This Year
- CRI N/A
- GERN $31,918.56
- Revenue Next Year
- CRI N/A
- GERN $289.41
- P/E Ratio
- CRI $8.22
- GERN N/A
- Revenue Growth
- CRI N/A
- GERN 9199.68
- 52 Week Low
- CRI $49.65
- GERN $1.64
- 52 Week High
- CRI $88.03
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- CRI 46.71
- GERN 31.98
- Support Level
- CRI $50.61
- GERN $2.49
- Resistance Level
- CRI $53.66
- GERN $2.84
- Average True Range (ATR)
- CRI 1.73
- GERN 0.15
- MACD
- CRI 0.07
- GERN -0.01
- Stochastic Oscillator
- CRI 60.35
- GERN 13.33
About CRI Carter's Inc.
Carter's Inc makes apparel for babies and children under brand names including Carter's and OshKosh B'gosh. It sells its products through a multi-channel business model, which includes retail stores, eCommerce, and wholesale sales channels, as well as retail omnichannel capabilities in the United States and Canada, which enables it to reach a broad range of consumers around the world. The company operates in three segments; U.S. Retail, U.S. Wholesale, and International. The majority of Carter's sales are in the U.S. and through Carter's brand. The company predominantly sources products through contract manufacturers in Asia. It has multiple distribution centers in the U.S., in addition to distribution centers in Canada and Asia that serve international customers.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.